Reneuron Stem Cell Retinitis Pigmentosa

Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying.

Reneuron stem cell retinitis pigmentosa.

Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us. Thu 10 september 2020 16 00 a a a. Reneuron upbeat on retinitis pigmentosa therapy development. We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development.

Reneuron group plc aim. About reneuron we are a leading clinical stage stem cell business. Pre clinical studies carried out in disease models by the our academic collaborators have demonstrated that when transplanted into the retina our hrpc technology has the potential to preserve existing photoreceptors. Rp is a group of hereditary.

Our exosomes are derived from our ctx human neural stem cell line. 2a clinical trial of its hrpc cell therapy candidate in retinitis pigmentosa. Clinical development of hrpc for retinitis pigmentosa a blindness causing disease of the retina is progressing in the us and we have the. From our ctx human neural stem cell line.